• Users Online: 277
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 4  |  Issue : 1  |  Page : 30-34

The effect of treatment duration on metabolic parameters in patients with prolactinoma: A prospective longitudinal study


1 Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
2 Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran; Clinical Research Development Unit, Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran

Correspondence Address:
Dr. Mehrnaz Imani
Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jdep.jdep_2_19

Rights and Permissions

Background: Hyperprolactinemia is associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) has been suggested to reverse these abnormalities. The present study was designed to determine the effect of treatment duration on metabolism as well as metabolic alterations after treatment in comparison with baseline in patients with prolactinoma in Iranian individuals. Methods: In a prospective and longitudinal study, 27 consecutive patients with prolactinoma were assessed during 6 months. Anthropometric data and metabolic variables were studied at baseline and at 3 and 6 months after normalization of PRL. Results: In the present study, there was a statistically significant decrease of metabolic syndrome (Met.S) after 3 months (P = 0.01), with a further decline after 6 months (P < 0.001) of cabergoline therapy. Moreover, a statistically significant decline was seen in total cholesterol (P = 0.007 and P = 0.01 after 3 and 6 months, respectively) and uric acid (P = 0.05 and P = 0.03 after 3 and 6 months, respectively) after normalization of the serum PRL. Conclusions: We found a significant reduction in Met.S after normalization of PRL level in patients with prolactinoma. We suggest that it is important to consider the metabolic profile of patients with prolactinoma. Then, patients may benefit even at 3 months after treatment.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1118    
    Printed70    
    Emailed0    
    PDF Downloaded82    
    Comments [Add]    

Recommend this journal